Speaker Profile
Ph.D., CEO and Co-Founder, Matterworks
Biography
Jack Geremia is a serial founder, company builder and executive, working at the intersection of the life sciences and machine learning. At Matterworks AI he is leading a team developing foundation models for predictive translation in drug discovery and development. Jack has spent more than 25 years in biotechnology and pharmaceutical R&D, including as co-founder and VP of R&D at Kaleido Biosciences, founder and CSO of Midori Animal Health, and Global Head of Discovery at DSM. He received his PhD in in chemistry from Princeton University and was a Gordon Moore Senior Postdoctoral Fellow in Information Science at the California Institute of Technology.
Talk
Foundation Models for Predictive Translation
The biochemome is the most proximal molecular readout of phenotype and the missing signal for predictive translation in drug development. AI foundation models, trained on >20 billion raw chemical spectra, quantify a compound’s direct biological response, distinguishing mechanism-driven bioactivity from on- and off-target toxicity in a single unbiased measurement.
AI for Emerging Therapeutics Showcase:
Matterworks, Inc.
Matterworks is a frontier AI company advancing predictive translation for drug discovery and development. Its spectral foundation models, delivered through its Pyxis co-scientist, read the biochemome from raw instrument data to help drug developers identify targets, flag safety liabilities earlier, and stratify patients.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 AI for Emerging Therapeutics Showcase will provide a 15-30 minute time slot for selected companies to explore the transformative role of artificial intelligence in accelerating the discovery, development, and optimization of novel therapeutic modalities. From predictive algorithms for drug efficacy to real-time analysis in clinical trials, AI is revolutionizing the way we approach emerging therapies, including RNA-based treatments, gene editing, and personalized medicine. Industry leaders and experts will discuss AI-driven advancements, collaborative frameworks, and the challenges of integrating cutting-edge technologies into therapeutic innovation. Join us for an in-depth look at how AI is shaping the future of breakthrough therapeutics.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
